Values First Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Values First Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$295K	Sell	71,351 -1,296	-2%	-$4.39K	0.14%	148
2026 Q2	$267K	Sell	72,647 -1,589	-2%	-$5.29K	0.12%	158
2026 Q1	$228K	Buy	74,236 +2,043	+3%	+$7.9K	0.12%	155
2025 Q4	$295K	Sell	72,193 -17,022	-19%	-$84.3K	0.15%	139
2025 Q3	$435K	Sell	89,215 -1,759	-2%	-$9.24K	0.23%	114
2025 Q2	$460K	Buy	90,974 +1,011	+1%	+$4.97K	0.25%	111
2025 Q1	$481K	Buy	89,963 +188	+0.2%	+$1.37K	0.28%	100
2024 Q4	$607K	Buy	89,775 +29,552	+49%	+$199K	0.33%	82
2024 Q3	$397K	Sell	60,223 -1,540	-2%	-$11K	0.22%	108
2024 Q2	$463K	Sell	61,763 -370	-0.6%	-$3.23K	0.28%	90
2024 Q1	$619K	Buy	62,133 +2,928	+5%	+$32.6K	0.36%	77
2023 Q4	$584K	Buy	59,205 +6,140	+12%	+$43.8K	0.35%	87
2023 Q3	$406K	Sell	53,065 -361	-0.7%	-$3.6K	0.26%	106
2023 Q2	$399K	Buy	53,426 +23,137	+76%	+$162K	0.24%	109
2023 Q1	$202K	Buy	+30,289	New	+$240K	0.13%	137

Other funds holding RXRX

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

Values First Advisors's RXRX Position: Q3 2026 in Review

Values First Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 1.8% in Q3 2026, selling an estimated $4.39K and leaving 71,351 shares worth $295K. The position accounts for 0.14% of the portfolio, ranked #148.

Values First Advisors first reported a position in RXRX in Q1 2023 and has held it in 15 quarters since. The position peaked at $619K in Q1 2024. 69 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Values First Advisors held 71,351 shares of Recursion Pharmaceuticals worth $295K as of Q3 2026.
Values First Advisors sold 1,296 Recursion Pharmaceuticals shares in Q3 2026, an estimated $4.39K.
Recursion Pharmaceuticals made up 0.14% of Values First Advisors's portfolio in Q3 2026, its #148 holding.
Values First Advisors first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
Values First Advisors's Recursion Pharmaceuticals position peaked at $619K in Q1 2024.
69 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.